

8 September 2014

**MD & CEO, DR GREG COLLIER, DISCUSSES WITH BRR MEDIA THE UPDATE ON
INVION'S PHASE II STUDY OF INV103 (ala-Cpn10) IN LUPUS PATIENTS**

Clinical-stage drug development company Invion Limited (ASX:IVX) is delighted to invite investors to listen to Managing Director and CEO, Dr Greg Collier, as he provides further background to today's announcement regarding interim data and progress of Invion's phase II clinical trial in patients with Systemic Lupus Erythematosus (SLE or lupus). In this audiocast, Dr Collier discusses:

- Interim data from the first two cohorts of the phase II clinical trial in lupus patients
- Next steps for this clinical trial and program
- INV103 (ala-Cpn10) and Invion's three drug asset pipeline

To access the audiocast, please visit this link: www.brrmedia.com/event/126913

FOR MORE INFORMATION CONTACT:

Managing Director and CEO
Dr Greg Collier
investor@inviongroup.com

MEDIA QUERIES:

Ben Walsh
Buchan Consulting
T: 02 9237 2800 or bwalsh@buchanwe.com.au

About INV103 (ala-Cpn10)

INV103 (ala-Cpn10) is a modified version of a naturally occurring human protein. It has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family - a critical component of prevention of autoimmunity. Data to date includes dose response reduction in biomarkers of inflammation including serum IL-6, MCP1, TNF and IL-1 and a strong safety profile in greater than 250 patients. INV103 (ala-Cpn10) has composition of matter protection in all the major markets.

About Invion Limited

Invision is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. INV102 (nadolol), a beta blocker (beta adrenergic biased ligand) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX) with its clinical headquarters in Delaware, USA.